News & Events about Affimed Nv.
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of AFM28 clinical development in the first half of 2023 on track HEIDELBERG, Germany, Dec. 22, 2022 (...
AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)Leukemia cell lysis was independent of differences in ...
Globe Newswire
2 months ago
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumorInitial signs of clinical activity and a well-managed safety profile with no dose-limiting toxicities were shown in preliminary data from the ...
Globe Newswire
2 months ago
Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patientsAffimeds AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive lymphoma patientsAB-101 is ...
Globe Newswire
2 months ago
In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment of AFM13 with allogeneic NK cells continues to achieve a 100% overall response rate and an improved 70.8% complete response rate Patients received up to four cycles and the treatment was very well...